Transactions
Jan. 8, 2002
AMGEN BUYS IMMUNEX IN BIG BIOTECH MARRIAGE
In the largest biotechnology merger in the United States, Amgen Inc. has acquired Immunex Corp. The stock and cash deal, announced Dec. 17, is worth $16 billion.
Thousand Oaks-based Amgen sells drugs for nephrology, cancer, inflammatory disorders and metabolic and neurodegenrenative disorders. Its signature products are EPOGEN, an anti-anemia drug and NEUPOGEN, a drug taken duri...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In